Information Provided By:
Fly News Breaks for November 9, 2015
INCY
Nov 9, 2015 | 06:59 EDT
Brean Capital recommends investors buy the dip in Incyte shares as the safety profile from its ongoing proof-of-concept Phase 1/2 trial with epacadostat in melanoma appears favorable. Brean Capital reiterated its Buy rating and $131 price target on Incyte shares.
News For INCY From the Last 2 Days
There are no results for your query INCY